---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-034334"
form_type: "8-K"
ticker: "BBLG"
cik: "0001419554"
company_name: "Bone Biologics Corp"
filed_at: "2026-07-23T12:05:26+00:00"
generated_at: "2026-07-23T12:10:23.904855+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bone Biologics raises $3M, extends runway to Q2 2027, advances NB1 study

## Summary
- Completed $3.0M private placement with healthcare-focused institutional investor; warrants could add up to $6.0M if exercised.
- Operating runway extended through Q2 2027; proceeds to fund clinical trials, patent portfolio, and working capital.
- NB1 first-in-human pilot study enrollment expected to complete by year-end 2026; interim updates possible.
- Validated shelf life of rhNELL-1 protein extended to 29 months, up from 24 months in December 2025.
- CEO Jeff Frelick highlights progress on 2026 priorities: clinical execution, product stability, IP protection, capital visibility.

## SEC filing metadata
- accession: 0001493152-26-034334
- form_type: 8-K
- ticker: BBLG
- cik: 0001419554
- company_name: Bone Biologics Corp
- filed_at: 2026-07-23T12:05:26+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419554/000149315226034334/0001493152-26-034334-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419554/000149315226034334/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-034334
- JSON: https://secwatch.observer/filing/0001493152-26-034334.json
- Plain text: https://secwatch.observer/filing/0001493152-26-034334.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.